文献速递产科母胎医学

扩展性常规早孕期筛查

Expanded conventional first trimester screening.
PubMed 文献 · Prenat Diagn · 2017-07-18

研究分析331例未患病、34例T21、19例T18和8例T13病例的五种血清标志物联合超声筛查方案表现。在1/300风险阈值下,T21检出率98%、假阳性率1.2%;T18/13在1/150阈值下检出率95%、假阳性率0.5%。结论认为扩展性常规筛查可获得高检出率和低假阳性率,并契合以游离DNA为次级或反射检测的 contingent 方案。

要点

  • T21筛查:五种血清标志物联合颈项透明层和鼻骨,1/300阈值下检出率98%、假阳性率1.2%。
  • T21筛查:1/1000阈值下检出率99%、假阳性率2.6%。
  • T18/13筛查:四种标志物联合颈项透明层,1/150阈值下检出率95%、假阳性率0.5%。

核心结论

  • 扩展性常规筛查试验可获得非常高的检出率和低假阳性率。
  • 该筛查契合以游离DNA作为次级或反射检测的 contingent 方案。
  • 该筛查还可识别其他不良结局(如早发型子痫前期)风险的妊娠。

研究设计与样本

  • 研究分析331例未患病、34例T21、19例T18和8例T13病例的标本。
  • 检测游离β人绒毛膜促性腺激素、妊娠相关血浆蛋白A、甲胎蛋白、胎盘生长因子和二聚体抑制素A。
  • 采用中位数倍数的高斯分布估算模拟假阳性率和检出率。

主要发现

  • T21:五种血清标志物联合颈项透明层和鼻骨,1/300风险阈值下检出率98%、假阳性率1.2%。
  • T21:1/1000阈值下检出率99%、假阳性率2.6%。
  • T18/13:游离β人绒毛膜促性腺激素、妊娠相关血浆蛋白A、胎盘生长因子和颈项透明层联合,1/150阈值下检出率95%、假阳性率0.5%。
  • T18/13:1/500风险阈值下检出率97%、假阳性率1.2%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The study aims to determine the performance of a five (5) serum marker plus ultrasound screening protocol for T21, T18 and T13. METHOD: Specimens from 331 unaffected, 34 T21, 19 T18 and 8 T13 cases were analyzed for free Beta human chorionic gonadotropin, pregnancy-associated plasma protein A, alpha-fetoprotein, placental growth factor and dimeric inhibin A. Gaussian distributions of multiples of the median values were used to estimate modeled false positive and detection rates (DR). RESULTS: For T21, at a 1/300 risk cut-off, DR of screening with all five serum markers along with nuchal translucency and nasal bone was 98% at a 1.2% false positive rate (FPR). Using a 1/1000 cut-off, the DR was 99% with a 2.6% FPR. For T18/13 with free Beta human chorionic gonadotropin, pregnancy-associated plasma protein A, placental growth factor and nuchal translucency at a 1/150 cut-off, DR was 95% at a 0.5% FPR while at a 1/500 risk cut-off, DR was 97% at a 1.2% FPR. CONCLUSION: An expanded conventional screening test can achieve very high DRs with low FPRs. Such screening fits well with proposed contingency protocols utilizing cell-free DNA as a secondary or reflex but also provides the advantages of identification of pregnancies at risk for other adverse outcomes such as early-onset preeclampsia. © 2017 Eurofins NTD, LLC. Prenatal Diagnosis published by John Wiley & Sons, Ltd.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Carmichael JB, Liu HP, Janik D, et al. Expanded conventional first trimester screening. Prenat Diagn. 2017. PMID: 28613385. doi:10.1002/pd.5090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。